Alternative splicing within the human cytochrome P450 superfamily with an emphasis on the brain: the convolution continues

• CUI X, KALSOTRA A, ROBIDA AM etal.: Expression of cytochromes P450 4F4 and 4F5 in infection and injury models of inflammation. Biochim. Biophys. Acta (2003) 1619(3):325-331.
   PubMed Web of Science ®Google Scholar
• KALSOTRA A, CUI X, ANTONOVIC L etal.: Inflammatory prompts produce isoform-specific changes in the expression of leukotriene B(4) -hydroxylases in rat liver and kidney. FEBS Lett. (2003) 555(2):236-242.
   PubMed Web of Science ®Google Scholar
• MICHELS R, MARZUK PM: Progress in psychiatry (2). N. Engl. J. Med. (1993) 329(9):628-638.
   PubMed Web of Science ®Google Scholar
• MICHELS R, MARZUK PM: Progress in psychiatry (1). N. Engl. J. Med. (1993) 329(8):552-560.
   PubMed Web of Science ®Google Scholar
• WILCOX RA, OWEN H: Variable cytochrome P450 2D6 expression and metabolism of codeine and other opioid prodrugs: implications for the Australian anaesthetist. Anaesth. Intensive Care (2000) 28(6):611-619.
   PubMed Web of Science ®Google Scholar
• BROCKMOLLER J, KIRCHHEINER J, MEISEL C, ROOTS I: Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment. Pharmacogenomics (2000) 1(2):125-151.
   PubMedGoogle Scholar
• DALY AK: Pharmacogenetics of the major polymorphic metabolizing enzymes. Fundam. Clin. Pharmacol. (2003) 17(1):27-41.
   PubMed Web of Science ®Google Scholar
• INGELMAN-SUNDBERG M: Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms. Naunyn Schmiedebergs Arch. Pharmacol. (2004) 369(1):89-104.
   PubMed Web of Science ®Google Scholar
• GUENGERICH FP, LIEBLER DC: Enzymatic activation of chemicals to toxic metabolites. Crit. Rev. Toxicol. (1985) 14(3):259-307.
   PubMed Web of Science ®Google Scholar
• NATION RL, EVANS AM, MILNE RW: Pharmacokinetic drug interactions with phenytoin (Part I). Clin. Pharmacokinet. (1990) 18(1):37-60.
   PubMed Web of Science ®Google Scholar
• GAD SC: Active drug metabolites in drug development. Curr. Opin. Pharmacol. (2003) 3(1):98-100.
   PubMed Web of Science ®Google Scholar
• NELSON DR, KOYMANS L, KAMATAKI T etal.: P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics (1996) 6(1):1-42.
   PubMedGoogle Scholar
• ANZENBACHER P, ANZENBACHEROVA E: Cytochromes P450 and metabolism of xenobiotics. Cell. Mol. Life Sci. (2001) 58(5-6):737-747.
   PubMed Web of Science ®Google Scholar
• NELSON DR, ZELDIN DC, HOFFMANSM etal.: Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics (2004) 14(1):1-18.
   PubMedGoogle Scholar
• HUTZLER M, MESSING DM, WIENKERS LC: Predicting drugdrug interactions in drug discovery: where are we now and where are we going? Curr. Opin. Drug Discov. Devel. (2005) 8(1):51-58.
   PubMed Web of Science ®Google Scholar
• TANG C, LIN JH, LU AY: Metabolism-based drugdrug interactions: what determines individual variability in cytochrome P450 induction? Drug Metab. Dispos. (2005) 33(5):603-613.
   PubMed Web of Science ®Google Scholar
• OZAWA S, SOYAMA A, SAEKI M etal.: Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1. Drug Metab. Pharmacokinet. (2004) 19(2):83-95.
   PubMedGoogle Scholar
• ROOTS I, GERLOFF T, MEISEL C etal.: Pharmacogenetics-based new therapeutic concepts. Drug Metab. Rev. (2004) 36(3-4):617-638.
   PubMed Web of Science ®Google Scholar
• EVANS DA, MAHGOUB A, SLOAN TP, IDLE JR, SMITH RL: A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J. Med. Genet. (1980) 17(2):102-105.
   PubMed Web of Science ®Google Scholar
• GONZALEZ FJ, SKODA RC, KIMURA S etal.: Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature (1988) 331(6155):442-446.
   PubMed Web of Science ®Google Scholar
• CROFT L, SCHANDORFF S, CLARK F etal.: ISIS, the intron information system, reveals the high frequency of alternative splicing in the human genome. Nat. Genet. (2000) 24(4):340-341.
   PubMed Web of Science ®Google Scholar
• SCHMUCKER D, CLEMENS JC, SHUH etal.: Drosophila Dscam is an axon guidance receptor exhibiting extraordinary molecular diversity. Cell (2000) 101(6):671-684.
   PubMed Web of Science ®Google Scholar
• LAREAU LF, GREEN RE, BHATNAGARRS, BRENNER SE: The evolving roles of alternative splicing. Curr. Opin. Struct. Biol. (2004) 14(3):273-282.
   PubMed Web of Science ®Google Scholar
• ZAPHIROPOULOS PG, FOLK WR, COON MJ: Isolation and characterization of a novel cytochrome P450-like pseudogene. Biochem. Biophys. Res. Commun. (1986) 134(2):499-505.
   PubMed Web of Science ®Google Scholar
• WONG G, KAWAJIRI K, NEGISHI M: Gene family of male-specific testosterone 16 -hydroxylase (C-P450(16)-) in mouse liver: cDNA sequences, neonatal imprinting, and reversible regulation by androgen. Biochemistry (1987) 26(26):8683-8690.
   PubMed Web of Science ®Google Scholar
• OKINO ST, QUATTROCHI LC, PENDURTHI UR, MCBRIDE OW, TUKEY RH: Characterization of multiple human cytochrome P450 1 cDNAs. The chromosomal localization of the gene and evidence for alternate RNA splicing. J. Biol. Chem. (1987) 262(33):16072-16079.
   PubMed Web of Science ®Google Scholar
• CHEN W, KUBOTA S, TERAMOTO T etal.: Silent nucleotide substitution in the sterol 27-hydroxylase gene (CYP 27) leads to alternative pre-mRNA splicing by activating a cryptic 5 splice site at the mutant codon in cerebrotendinous xanthomatosis patients. Biochemistry (1998) 37(13):4420-4428.
   PubMed Web of Science ®Google Scholar
• CHRISTMAS P, JONES JP, PATTEN CJ etal.: Alternative splicing determines the function of CYP4F3 by switching substrate specificity. J. Biol. Chem. (2001) 276(41):38166-38172.
   PubMed Web of Science ®Google Scholar
• PAI HV, KOMMADDI RP, CHINTA SJ etal.: A frameshift mutation and alternate splicing in human brain generate a functional form of the pseudogene cytochrome P4502D7 that demethylates codeine to morphine. J. Biol. Chem. (2004) 279(26):27383-27389.
   PubMed Web of Science ®Google Scholar
• BLACK DL: Mechanisms of alternative pre-messenger RNA splicing. Ann. Rev. Biochem. (2003) 72:291-336.
   PubMed Web of Science ®Google Scholar
• CARTEGNI L, CHEW SL, KRAINERAR: Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat. Rev. Genet. (2002) 3(4):285-298.
   PubMed Web of Science ®Google Scholar
• KUEHL P, ZHANG J, LIN Y etal.: Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. (2001) 27(4):383-391.
   PubMed Web of Science ®Google Scholar
• VERRIPS A, STEENBERGEN-SPANJERS GC, LUYTEN JA etal.: Exon skipping in the sterol 27-hydroxylase gene leads to cerebrotendinous xanthomatosis. Hum. Genet. (1997) 100(2):284-286.
   PubMed Web of Science ®Google Scholar
• MAAS RM, REUS K, DIESEL B etal.: Amplification and expression of splice variants of the gene encoding the P450 cytochrome 25-hydroxyvitamin D(3) 1,-hydroxylase (CYP 27B1) in human malignant glioma. Clin. Cancer Res. (2001) 7(4):868-875.
   PubMed Web of Science ®Google Scholar
• CHINTA SJ, KOMMADDI RP, TURMAN CM, STROBEL HW, RAVINDRANATH V: Constitutive expression and localization of cytochrome P450 1A1 in rat and human brain: presence of a splice variant form in human brain. J. Neurochem. (2005) 93(3):724-736.
   PubMed Web of Science ®Google Scholar
• ALLORGE D, CHEVALIER D, LO-GUIDICE JM etal.: Identification of a novel splice-site mutation in the CYP1A2 gene. Br. J. Clin. Pharmacol. (2003) 56(3):341-344.
   PubMed Web of Science ®Google Scholar
• DING S, LAKE BG, FRIEDBERG T, WOLF CR: Expression and alternative splicing of the cytochrome P450 CYP2A7. Biochem. J. (1995) 306(Pt 1):161-166.
   PubMed Web of Science ®Google Scholar
• BLUMENTHAL T: Gene clusters and polycistronic transcription in eukaryotes. Bioessays (1998) 20(6):480-487.
   PubMed Web of Science ®Google Scholar
• FINTA C, WARNER SC, ZAPHIROPOULOS PG: Intergenic mRNAs. Minor gene products or tools of diversity? Histol. Histopathol. (2002) 17(2):677-682.
   PubMed Web of Science ®Google Scholar
• FINTA C, ZAPHIROPOULOS PG: The human cytochrome P450 3A locus. Gene evolution by capture of downstream exons. Gene (2000) 260(1-2):13-23.
   PubMed Web of Science ®Google Scholar
• RODRIGUEZ-ANTONA C, AXELSONM, OTTER C, RANE A, INGELMAN-SUNDBERG M: A novel polymorphic cytochrome P450 formed by splicing of CYP3A7 and the pseudogene CYP3AP1. J. Biol. Chem. (2005) 280(31):28324-28331.
   PubMed Web of Science ®Google Scholar
• ZAPHIROPOULOS PG: RNA molecules containing exons originating from different members of the cytochrome P450 2C gene subfamily (CYP2C) in human epidermis and liver. Nucleic Acids Res. (1999) 27(13):2585-2590.
   PubMed Web of Science ®Google Scholar
• FINTA C, ZAPHIROPOULOS PG: Intergenic mRNA molecules resulting from trans-splicing. J. Biol. Chem. (2002) 277(8):5882-5890.
   PubMed Web of Science ®Google Scholar
• BRUDNO M, GELFAND MS, SPENGLER S etal.: Computational analysis of candidate intron regulatory elements for tissue-specific alternative pre-mRNA splicing. Nucleic Acids Res. (2001) 29(11):2338-2348.
   PubMed Web of Science ®Google Scholar
• MAHENDROO MS, MENDELSON CR, SIMPSON ER: Tissue-specific and hormonally controlled alternative promoters regulate aromatase cytochrome P450 gene expression in human adipose tissue. J. Biol. Chem. (1993) 268(26):19463-19470.
   PubMed Web of Science ®Google Scholar
• SHOZU M, ZHAO Y, BULUN SE, SIMPSON ER: Multiple splicing events involved in regulation of human aromatase expression by a novel promoter, I.6. Endocrinology (1998) 139(4):1610-1617.
   PubMed Web of Science ®Google Scholar
• CUI X, NELSON DR, STROBEL HW: A novel human cytochrome P450 4F isoform (CYP4F11): cDNA cloning, expression, and genomic structural characterization. Genomics (2000) 68(2):161-166.
   PubMed Web of Science ®Google Scholar
• DESROCHERS M, CHRISTOU M, JEFCOATE C, BELZIL A, ANDERSONA: New proteins in the rat CYP2B subfamily: presence in liver microsomes of the constitutive CYP2B3 protein and the phenobarbital-inducible protein product of alternatively spliced CYP2B2 mRNA. Biochem. Pharmacol. (1996) 52(8):1311-1319.
   PubMed Web of Science ®Google Scholar
• BLACK VH, WANG A, HENRY M, SHAW P: Molecular cloning of cDNA for guinea pig CYP1A2 comparison with guinea pig CYP1A1. Arch. Biochem. Biophys. (1997) 344(1):11-17.
   PubMed Web of Science ®Google Scholar
• GRAM TE, OKINE LK, GRAM RA: The metabolism of xenobiotics by certain extrahepatic organs and its relation to toxicity. Ann. Rev. Pharmacol. Toxicol. (1986) 26:259-291.
   PubMed Web of Science ®Google Scholar
• BOYD MR: Biochemical mechanisms in chemical-induced lung injury: roles of metabolic activation. Crit. Rev. Toxicol. (1980) 7(2):103-176.
   PubMed Web of Science ®Google Scholar
• GRABOWSKI PJ, BLACK DL: Alternative RNA splicing in the nervous system. Prog. Neurobiol. (2001) 65(3):289-308.
   PubMed Web of Science ®Google Scholar
• GONZALEZ FJ: Human cytochromes P450: problems and prospects. Trends Pharmacol. Sci. (1992) 13(9):346-352.
   PubMed Web of Science ®Google Scholar
• BROSEN K: Recent developments in hepatic drug oxidation. Implications for clinical pharmacokinetics. Clin. Pharmacokinet. (1990) 18(3):220-239.
   PubMed Web of Science ®Google Scholar
• STROBEL HW, THOMPSON CM, ANTONOVIC L: Cytochromes P450 in brain: function and significance. Curr. Drug Metab. (2001) 2(2):199-214.
   PubMed Web of Science ®Google Scholar
• MORTIMER O, PERSSON K, LADONAMG etal.: Polymorphic formation of morphine from codeine in poor and extensive metabolizers of dextromethorphan: relationship to the presence of immunoidentified cytochrome P450IID1. Clin. Pharmacol. Ther. (1990) 47(1):27-35.
   PubMed Web of Science ®Google Scholar
• SINDRUP SH, ARENDT-NIELSEN L, BROSEN K etal.: The effect of quinidine on the analgesic effect of codeine. Eur. J. Clin. Pharmacol. (1992) 42(6):587-591.
   PubMed Web of Science ®Google Scholar
• CHEN ZR, IRVINE RJ, BOCHNER F, SOMOGYI AA: Morphine formation from codeine in rat brain: a possible mechanism of codeine analgesia. Life Sci. (1990) 46(15):1067-1074.
   PubMed Web of Science ®Google Scholar
• SINDRUP SH, BROSEN K, BJERRING P etal.: Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine. Clin. Pharmacol. Ther. (1990) 48(6):686-693.
   PubMed Web of Science ®Google Scholar
• BROSEN K, SINDRUP SH, SKJELBO E, NIELSEN KK, GRAM LF: Role of genetic polymorphism in psychopharmacology an update. Psychopharmacol. Ser. (1993) 10:199-211.
   PubMedGoogle Scholar
• YU AM, IDLE JR, HERRAIZ T, KUPFERA, GONZALEZ FJ: Screening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase. Pharmacogenetics (2003) 13(6):307-319.
   PubMedGoogle Scholar
• YU AM, IDLE JR, BYRD LG etal.: Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. Pharmacogenetics (2003) 13(3):173-181.
   PubMedGoogle Scholar
• FUNAE Y, KISHIMOTO W, CHO T, NIWA T, HIROI T: CYP2D in the brain. Drug Metab. Pharmacokinet. (2003) 18(6):337-349.
   PubMedGoogle Scholar
• ZHUGE J, YU YN: Three new alternative splicing variants of human cytochrome P450 2D6 mRNA in human extratumoral liver tissue. World J. Gastroenterol. (2004) 10(22):3356-3360.
   PubMed Web of Science ®Google Scholar
• WOO SI, HANSEN LA, YU X, MALLORY M, MASLIAH E: Alternative splicing patterns of CYP2D genes in human brain and neurodegenerative disorders. Neurology (1999) 53(7):1570-1572.
   PubMed Web of Science ®Google Scholar
• HUANG Z, FASCO MJ, KAMINSKY LS: Alternative splicing of CYP2D mRNA in human breast tissue. Arch. Biochem. Biophys. (1997) 343(1):101-108.
   PubMed Web of Science ®Google Scholar
• GAEDIGK A, GAEDIGK R, LEEDER JS: CYP2D7 splice variants in human liver and brain: does CYP2D7 encode functional protein? Biochem. Biophys. Res. Commun. (2005) 336(4):1241-1250.
   Google Scholar
• SCOTT EE, HE YQ, HALPERT JR: Substrate routes to the buried active site may vary among cytochromes P450: mutagenesis of the F-G region in P450 2B1. Chem. Res. Toxicol. (2002) 15(11):1407-1413.
   PubMed Web of Science ®Google Scholar
• GUENGERICH FP, HANNA IH, MARTIN MV, GILLAM EM: Role of glutamic acid 216 in cytochrome P450 2D6 substrate binding and catalysis. Biochemistry (2003) 42(5):1245-1253.
   PubMed Web of Science ®Google Scholar
• WHITLOCK JP, JR.: Induction of cytochrome P4501A1. Ann. Rev. Pharmacol. Toxicol. (1999) 39:103-125.
   PubMed Web of Science ®Google Scholar
• BERESFORD AP: CYP1A1: friend or foe? Drug Metab. Rev. (1993) 25(4):503-517.
   PubMed Web of Science ®Google Scholar
• VASQUEZ HG, STROBEL H: Identification of cytochrome P450s in human glioma cell line. Int. J. Oncol. (1998) 12(6):1291-1294.
   PubMed Web of Science ®Google Scholar
• GENG J, STROBEL HW: Expression, induction and regulation of the cytochrome P450 monooxygenase system in the rat glioma C6 cell line. Brain Res. (1998) 784(1-2):276-283.
   PubMed Web of Science ®Google Scholar
• KOMMADDI RP, TURMAN CM, MOORTHY B etal.: An alternate spliced cytochrome P4501A1, a xenobiotic metabolizing enzyme, present in human brain does not bioactivate arylhydrocarbons to carcinogenic DNA binding metabolite(s). Manuscript submitted (2005).
   Google Scholar
• GERVASINI G, CARRILLO JA, BENITEZ J: Potential role of cerebral cytochrome P450 in clinical pharmacokinetics: modulation by endogenous compounds. Clin. Pharmacokinet. (2004) 43(11):693-706.
   PubMed Web of Science ®Google Scholar
• NIWA T, HIROI T, TSUZUKI D etal.: Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res. Mol. Brain Res. (2004) 129(1-2):117-123.
   PubMedGoogle Scholar
• LEE C, ATANELOV L, MODREK B, XING Y: ASAP: the Alternative Splicing Annotation Project. Nucleic Acids Res. (2003) 31(1):101-105.
   PubMed Web of Science ®Google Scholar
• LEUNG YK, LAU KM, MOBLEY J, JIANG Z, HO SM: Overexpression of cytochrome P450 1A1 and its novel spliced variant in ovarian cancer cells: alternative subcellular enzyme compartmentation may contribute to carcinogenesis. Cancer Res. (2005) 65(9):3726-3734.
   PubMed Web of Science ®Google Scholar
• SCHWEIKL H, TAYLOR JA, KITAREEWAN S etal.: Expression of CYP1A1 and CYP1A2 genes in human liver. Pharmacogenetics (1993) 3(5):239-249.
   PubMedGoogle Scholar
• MILES JS, MCLAREN AW, WOLF CR: Alternative splicing in the human cytochrome P450IIB6 gene generates a high level of aberrant messages. Nucleic Acids Res. (1989) 17(20):8241-8255.
   PubMed Web of Science ®Google Scholar
• LAMBA V, LAMBA J, YASUDA K etal.: Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J. Pharmacol. Exp. Ther. (2003) 307(3):906-922.
   PubMed Web of Science ®Google Scholar
• FINTA C, ZAPHIROPOULOS PG: The human CYP2C locus: a prototype for intergenic and exon repetition splicing events. Genomics (2000) 63(3):433-438.
   PubMed Web of Science ®Google Scholar
• WARNER SC, FINTA C, ZAPHIROPOULOS PG: Intergenic transcripts containing a novel human cytochrome P450 2C exon 1 spliced to sequences from the CYP2C9 gene. Mol. Biol. Evol. (2001) 18(10):1841-1848.
   PubMed Web of Science ®Google Scholar
• ZAPHIROPOULOS PG: Exon skipping and circular RNA formation in transcripts of the human cytochrome P450 2C18 gene in epidermis and of the rat androgen binding protein gene in testis. Mol. Cell. Biol. (1997) 17(6):2985-2993.
   PubMed Web of Science ®Google Scholar
• HUANG Z, FASCO MJ, SPIVACK S, KAMINSKY LS: Comparisons of CYP2D messenger RNA splice variant profiles in human lung tumors and normal tissues. Cancer Res. (1997) 57(13):2589-2592.
   PubMed Web of Science ®Google Scholar
• YAMAKOSHI Y, KISHIMOTO T, SUGIMURA K, KAWASHIMA H: Human prostate CYP3A5: identification of a unique 5-untranslated sequence and characterization of purified recombinant protein. Biochem. Biophys. Res. Commun. (1999) 260(3):676-681.
   PubMed Web of Science ®Google Scholar
• BUSI F, CRESTEIL T: CYP3A5 mRNA degradation by nonsense-mediated mRNA decay. Mol. Pharmacol. (2005) 68(3):808-815.
   PubMed Web of Science ®Google Scholar
• BUSI F, CRESTEIL T: Phenotyping-genotyping of alternatively spliced genes in one step: study of CYP3A5*3 polymorphism. Pharmacogenet. Genomics (2005) 15(6):433-439.
   PubMed Web of Science ®Google Scholar
• CHABRE O, PORTRAT-DOYEN S, CHAFFANJON P etal.: Bilateral laparoscopic adrenalectomy for congenital adrenal hyperplasia with severe hypertension, resulting from two novel mutations in splice donor sites of CYP11B1. J. Clin. Endocrinol. Metab. (2000) 85(11):4060-4068.
   PubMed Web of Science ®Google Scholar
• CHABRE O, PORTRAT-DOYEN S, VIVIER J, MOREL Y, DEFAYE G: Two novel mutations in splice donor sites of CYP11B1 in congenital adrenal hyperplasia due to 11-hydroxylase deficiency. Endocr. Res. (2000) 26(4):797-801.
   PubMed Web of Science ®Google Scholar
• COSTA-SANTOS M, KATER CE, DIASEP, AUCHUS RJ: Two intronic mutations cause 17-hydroxylase deficiency by disrupting splice acceptor sites: direct demonstration of aberrant splicing and absent enzyme activity by expression of the entire CYP17 gene in HEK-293 cells. J. Clin. Endocrinol. Metab. (2004) 89(1):43-48.
   PubMed Web of Science ®Google Scholar
• YAMAGUCHI H, NAKAZATO M, MIYAZATO M etal.: Identification of a novel splicing mutation and 1-bp deletion in the 17-hydroxylase gene of Japanese patients with 17-hydroxylase deficiency. Hum. Genet. (1998) 102(6):635-639.
   PubMed Web of Science ®Google Scholar
• MEANS GD, KILGORE MW, MAHENDROO MS, MENDELSON CR, SIMPSON ER: Tissue-specific promoters regulate aromatase cytochrome P450 gene expression in human ovary and fetal tissues. Mol. Endocrinol. (1991) 5(12):2005-2013.
   PubMed Web of Science ®Google Scholar
• SIMPSON ER, MAHENDROO MS, MEANS GD etal.: Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocr. Rev. (1994) 15(3):342-355.
   PubMed Web of Science ®Google Scholar
• SEBASTIAN S, BULUN SE: A highly complex organization of the regulatory region of the human CYP19 (aromatase) gene revealed by the Human Genome Project. J. Clin. Endocrinol. Metab. (2001) 86(10):4600-4602.
   PubMed Web of Science ®Google Scholar
• HIGASHI Y, TANAE A, INOUE H, HIROMASA T, FUJII-KURIYAMA Y: Aberrant splicing and missense mutations cause steroid 21-hydroxylase [P450(C21)] deficiency in humans: possible gene conversion products. Proc. Natl. Acad. Sci. USA (1988) 85(20):7486-7490.
   PubMed Web of Science ®Google Scholar
• LEE HH, CHANG SF: Multiple transcripts of the CYP21 gene are generated by the mutation of the splicing donor site in intron 2 from GT to AT in 21-hydroxylase deficiency. J. Endocrinol. (2001) 171(3):397-402.
   PubMed Web of Science ®Google Scholar
• SCHULZE E, BETTENDORF M, MASER-GLUTH C, DECKER M, SCHWABE U: Allele-dropout using PCR-based diagnosis for the splicing mutation in intron-2 of the CYP21B-gene: successful amplification with a Taq/Pwo-polymerase mixture. Endocr. Res. (1998) 24(3-4):637-641.
   PubMed Web of Science ®Google Scholar
• REN S, NGUYEN L, WU S etal.: Alternative splicing of vitamin D-24-hydroxylase: a novel mechanism for the regulation of extrarenal 1,25-dihydroxyvitamin D synthesis. J. Biol. Chem. (2005) 280(21):20604-20611.
   PubMed Web of Science ®Google Scholar
• GARUTI R, LELLI N, BAROZZINI M etal.: Cerebrotendinous xanthomatosis caused by two new mutations of the sterol-27-hydroxylase gene that disrupt mRNA splicing. J. Lipid Res. (1996) 37(7):1459-1467.
   PubMed Web of Science ®Google Scholar
• CHEN W, KUBOTA S, SEYAMA Y: Alternative pre-mRNA splicing of the sterol 27-hydroxylase gene (CYP 27) caused by a G to A mutation at the last nucleotide of exon 6 in a patient with cerebrotendinous xanthomatosis (CTX). J. Lipid Res. (1998) 39(3):509-517.
   PubMed Web of Science ®Google Scholar
• CHEN W, KUBOTA S, UJIKE H, ISHIHARA T, SEYAMA Y: A novel Arg362Ser mutation in the sterol 27-hydroxylase gene (CYP27): its effects on pre-mRNA splicing and enzyme activity. Biochemistry (1998) 37(43):15050-15056.
   PubMed Web of Science ®Google Scholar
• CHRISTMAS P, URSINO SR, FOX JW, SOBERMAN RJ: Expression of the CYP4F3 gene. tissue-specific splicing and alternative promoters generate high and low K(m) forms of leukotriene B(4) -hydroxylase. J. Biol. Chem. (1999) 274(30):21191-21199.
   PubMed Web of Science ®Google Scholar
• SCHUG J, OVERTON GC: Transcription Element Search Software on the WWW. Technical Report (CBIL-TR-1997-1001-v0.0), Computational Biology and Informatics Laboratory University of Pennsylvania, School of Medicine (1998).
   Google Scholar

Website

• http://www.imm.ki.se/CYPalleles/ Home page of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee (2001).
   Google Scholar